Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results

ByConnor Hodde

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read the entire article here.

Similar Posts

Scientists Develop Animal Model for TB-Related Blindness

ByConnor Hodde

Tuberculosis experts at Johns Hopkins and elsewhere have closely mimicked how active but untreated cases of the underlying lung infection lead to permanent eye damage and blindness in people.Lead study investigator and Johns Hopkins infectious disease specialist Petros Karakousis, M.D., says the new animal model should hasten development of a badly needed, early diagnostic test…

Retinal microvascular changes associated with disability in daily activities among older adults

ByConnor Hodde

Retinal microvascular changes appear to be associated with development of disability in performing activities of daily living among older adults, and retinal signs may be useful in predicting outcomes among this population, according to a report published Online First by Archives of Ophthalmology. http://medicalxpress.com/news/2011-11-retinal-microvascular-disability-daily-older.html

Spark Surges in IPO as Prices Fuel Gene Therapy

ByConnor Hodde

Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug.  The treatments focus on diseases where a single mutation in the genetic code is known to be…

Nanotechnology-Based Cancer Treatment Can Reduce Side Effects

ByConnor Hodde

Conventional cancer treatments are accompanied by a host of side effects such as nausea and vomiting. The intensity of the side effects is many a time so acute that it poses a deterrent to further treatment. The reason behind the side effects is that existing cancer treatment methods do not address just the cancerous cells,…

EyeCRO Receives Full Accreditation from AAALAC International for its Research Facilities

ByPhotoreceptor

EyeCRO LLC has been awarded full accreditation from AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and the University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to receive this prestigious endorsement. The award letter from…

Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)

ByConnor Hodde

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. Read the entire article here.